Tolerability and use in co-administration of pregabalin in affective patients: A 6-month prospective naturalistic study

Expert Opinion on Drug Safety

Volumn 11, Issue 6, 2012, Pages 893-899

  Dobrea, Cristina ^a   Buoli, Massimiliano ^a   Arici, Chiara ^a   Camuri, Giulia ^a   Dell'Osso, Bernardo ^a   Altamura, Alfredo Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Affective disorders; Benzodiazepines; Polytherapy; Pregabalin; Tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AFFECTIVE NEUROSIS; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; NAUSEA; ONSET AGE; OUTPATIENT; PERIPHERAL EDEMA; PRESCRIPTION; PSYCHIATRIC DIAGNOSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUBSTANCE ABUSE; THYROID DISEASE; TRANQUILIZING ACTIVITY;

ADULT; AGED; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; OUTPATIENTS; PROSPECTIVE STUDIES;

EID: 84867817170     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.720971     Document Type: Article

References (51)

1. Marks DM, Patkar AA, Masand PS, et al. Does pregabalin have neuropsychotropic effects? A short perspective. Psychiatry Investig 2009;6:55-8
2. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2007;3:185-91
3. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000;280:107-10
4. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003;105:133-41
5. Geracioti TD Jr, Carpenter LL, Owens MJ, et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 2006;163:637-43
6. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [3H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-93
7. Strawn JR, Thomas D Geracioti TD Jr. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr Dis Treat 2007;3:237-43
8. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46:1407-13
9. Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010;50:941-50
10. Allgulander C. Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 2010;23:37-42
11. EMEA. European Medicines Agency. Lyrica-scientific discussion, 2006
12. Showraki M. Pregabalin in the treatment of depression. J Psychopharmacol 2007;21:883-4
13. Stein DJ, Baldwin DS, Baldinetti F, et al. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008;18:422-30
14. Westenberg HG. Recent advances in understanding and treating social anxiety disorder. CNS Spectr 2009;14:24-33
15. Bandelow B. The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr 2008;13:37-46
16. Pae CU. Pregabalin augmentation to antidepressants in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:577-8
17. Oulis P, Konstantakopoulos G. Pregabalin in the treatment of alcohol and benzodiazepines dependence. CNS Neurosci Ther 2010;16:45-50
18. Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 2010;24:1367-74
19. Di Nicola M, Martinotti G, Tedeschi D, et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol 2010;25:268-75
20. Pae CU, Marks DM, Han C, et al. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int Clin Psychopharmacol 2009;24:29-33
21. Zohar J, Matar MA, Ifergane G, et al. Brief post-stressor treatment with pregabalin in an animal model for PTSD: short-term anxiolytic effects without long-term anxiogenic effect. Eur Neuropsychopharmacol 2008;18:653-66
22. Englisch S, Esser A, Enning F, et al. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010;30:437-40
23. Oulis P, Konstantakopoulos G, Kouzoupis AV, et al. Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum Psychopharmacol 2008;23:337-40
24. Biermann T, Bleich S, Kornhuber J, et al. Pregabalin in benzodiazepine withdrawal. Pharmacopsychiatry 2007;40:292-3
25. Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J Clin Psychiatry 2005;66:21-7
26. Bobes J, Rubio G, Terán A, et al. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry 2012;27:301-7
27. Skopp G, Zimmer G. Pregabalin-a drug with abuse potential? Arch Kriminol 2012;229:44-54
28. Schwan S, Sundstrom A, Stjernberg E, et al. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010;66:947-53
29. Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011;80:118-22
30. Schifano F, Leoni M, Martinotti G, et al. Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. Cyberpsychol Behav 2003;6:405-10
31. Frame B, Miller R, Hutmacher MM. Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder. J Pharmacokinet Pharmacodyn 2009;36:565-84
32. Lalovic B, Hutmacher M, Frame B, et al. Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder. J Clin Pharmacol 2011;51:706-18
33. Page RL II, Cantu M, Lindenfeld J, et al. Possible heart failure exacerbation associated with pregabalin: case discussion and literature review. J Cardiovasc Med (Hagerstown) 2008;9:922-5
34. Kamel JT, D'Souza WJ, Cook MJ. Severe and disabling constipation: an adverse effect of pregabalin. Epilepsia 2010;51:1094-6
35. Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011;45(6):e32
36. Ramsay RE, Perucca E, Robbins J, et al. Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures. Epilepsia 2009;50:1891-8
37. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text Revision American Psychiatric Association; Washington DC: 2000
38. First MB, Spitzer RL, NGibbon M, et al. Structured clinical interview for DSM-IV-TR axis I disorders. Patient edition. Research Version Biometrics Research, New York State Psychiatric Institute; (SCID-I/P) New York: 2002
39. First MB, Gibbon M, Spitzer RL, et al. Structured clinical interview for DSM-IV axis II personality disorders (SCID-II). American Psychiatric Press; Washington DC: 1997
40. Hamilton M. A rating scale for depression, Department of Psychiatry, University of Leeds. J Neurol Neurosurg Psichiat 1960;23:56-62
41. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
42. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
43. Guy W. Clinical global impressions. In: ECDEU assessment manual for psychopharmacology, revised DHEW Pub. (ADM). National Institute for Mental Health; Rockville, MD: 1976. p. 218-22
44. Oulis P, Florakis AA, Tzanoulinos G, et al. Adjunctive pregabalin to quetiapine in acute mania. Clin Neuropharmacol 2009;32:174
45. Lydiard RB, Rickels K, Herman B, et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010;13:229-41
46. Miceli JJ, Ramey TS, Weaver JJ, et al. Adjunctive pregabalin treatment after partial response in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. Presented at the 162nd Annual Meeting of the American Psychiatric Association; 16-21 May 2009; San Francisco, CA
47. Altamura AC, Dell'Osso B, Buoli M, et al. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study. Int Clin Psychopharmacol 2008;23:198-202
48. Buoli M, Dell'osso B, Bosi MF, et al. Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. Psychiatry Clin Neurosci 2010;64:612-19
49. Dell'Osso B, Buoli M, Baldwin DS, et al. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol 2010;25:17-29
50. Den Boer JA, Bosker FJ, Slaap BR. Serotonergic drugs in the treatment of depressive and anxiety disorders. Hum Psychopharmacol 2000;15:315-36
51. Taylor D. Venlafaxine and cardiovascular toxicity. BMJ 2010;340:c411